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Background: Early reperfusion of ischemic myocytes is essential for optimal salvage in acute myocardial infarc-
tion. VA (ventricular arrhythmia) bursts after recanalization of the culprit vessel have been found to be related
to larger infarct size (IS), using SPECT.
Objective: The hypothesis was tested that this ﬁnding could be conﬁrmed in an independent cohort using a more
accurate technique, i.e. delayed-enhancement cardiovascular magnetic resonance imaging (DE-CMR).
Methods: All 196 patients from the PREPARE and MAST studies who had 24-hour, continuous, 12-lead Holter,
started before primary percutaneous coronary intervention resulting in brisk TIMI (thrombolysis in myocardial
infarction) 3 ﬂow and stable ST-recovery were included. VA bursts were identiﬁed against subject-speciﬁc back-
ground VA rates using a previously published statistical outlier method. IS was assessed using DE-CMR. Angiog-
raphy, Holter and DE-CMR results were assessed in core laboratories, blinded to all other data.
Results: VA bursts were present in 154/196 (79%) of patients. Baseline characteristics between the groups with
and without bursts were similar. VA burst was associated with signiﬁcantly larger infarct size in the population
as a whole (median 11.3% vs 5.3%; p= 0.001) and also when divided in non-anterior (median 9.9% vs 4.9%; p=
0.003) and anterior myocardial infarction (median 21.4% vs 12.0%; p = 0.48), the latter not reaching statistical
signiﬁcance due to the small subset of patients.
Conclusion: Beyond the classical markers of “optimal” reperfusion such as TIMI 3 ﬂow and stable ST-segment re-
covery, VA bursts occurring during the reperfusion phase are an early electrobiomarker of larger IS. Clinical trial
registration: PREPARE: ISRCTN71104460 http://www.controlled-trials.com/ISRCTN71104460.© 2015 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Ventricular arrhythmias (VAs) upon reperfusion are recognized
as a typical phenomenon since the advent of recanalization tech-
niques in acute ST-elevation myocardial infarction (STEMI). Howev-
er, not much is known about their pathophysiological and prognostic
signiﬁcance [1]. Morphologically, these reperfusion VAs include ven-
tricular premature beats with long coupling intervals and accelerat-
ed idioventricular rhythms. They occur (almost) directly at the
moment of reperfusion, are hemodynamically well tolerated andiovascular magnetic resonance
taneous coronary intervention;
EMI, ST elevationmyocardial in-
entricular arrhythmias.
icine, AmstellandHospital, Laan
328, 1180 AH Amstelveen, The
er Weg).
.originate within the reperfusion zone (Fig. 1) [2]. In conjunction
with thrombolytic therapy, reperfusion VAs were considered a posi-
tive event as a non-invasive marker of infarct artery recanalization
[2]. In the more contemporary era of direct percutaneous coronary
intervention (PCI), where TIMI 3 epicardial ﬂow is restored in N90%
of STEMIs and mortality has been reduced to less than 5% [3], the hy-
pothesis that VA “bursts” are associated with larger infarct size (IS)
and worsened outcomes in the setting of anterior MI has been pro-
posed by our group, based on retrospective modeling [4–7].
Over the last years, it has become clear that clinically beneﬁcial re-
perfusion in STEMI is dependent on both the clinical context and on a
series of key mechanistic steps deﬁning “optimal” reperfusion per se.
Clinically, the timing of presentation relative to the ongoing irreversible
injury or “wavefront” of cell death has been addressed with emphasis
on early diagnosis and time to intervention and results in smaller IS
and lower morbidity [8–10]. IS as an endpoint was traditionally mea-
sured with SPECT imaging, but can now be measured with greater pre-
cision using delayed enhancement cardiovascular magnetic resonance
imaging (DE-CMR) [11].
Fig. 1. Full disclosure format of a 24 hour ambulatory recording illustrating the onset and
perpetuation of a reperfusion ventricular arrhythmia burst. Greenwaveforms: Sinus beats
still showing some ST segment elevation. Red waveforms: accelerated idioventricular
rhythm interrupting the sinus rhythm.
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erated by observations from Majidi et al. [4,5,19] to a unique patient
population with not only anterior STEMI but also non-anterior STEMI
and the use of DE-CMR, the current gold standard, for IS measurement.
In this population we examined whether it could be conﬁrmed that VA
burst adds signiﬁcantly to IS in patients with optimal reperfusion, as in-




Patients included in the Maastricht ST-Elevation Myocardial Infarc-
tion (MAST) cohort [12] and the Proximal embolic protection study in
patients undergoing primary angioplasty for acute myocardial infarc-
tion (PREPARE) cohort were included for analyses. The protocols of
both studies, speciﬁcally including Holter recording and CMR imaging,
were prospectively designed to answer the questions of the study at
hand. Since the PROXIS device used in the PREPARE trial did not inﬂu-
ence the ﬁnal infarct size, all patients from that study were included in
this analysis [13]. Approval of both studies was granted by the Medical
Ethical Committee of corresponding hospitals (MAST p06.0032L and
PREPARE ISRCTN71104460) and written informed consent was obtain-
ed from all patients included.
Both studies included patients enrolled between August 2006 and
June 2008. Inclusion criteria for both studies were as follows: (1) symp-
toms consistent with an acute STEMI lasting for more than 30 min but
less than 6 h and (2) ST-elevation of more than 1 mm in anatomically
adjacent leads in the initial electrocardiogram (ECG), and (3) primary
PCI. Exclusion criteria were as follows: (1) age below 18 years, (2) car-
diogenic shock, (3) pregnancy, (4) inability to obtain informed consent,
(5) any contraindications to the use of glycoprotein IIb/IIIa receptor an-
tagonists, (6) a co-existent condition associated with a limited life ex-
pectancy, (7) prior coronary artery bypass grafting or ﬁbrinolytics, and
(8) standard contra-indications for CMR.
In both studies, 24-hour, continuous, digital 12-lead ECG-Holter
monitoring was started at the time of admission, and CMR imaging
was scheduled 3 months after the acute event for analyses of ﬁnal in-
farct size after remodeling [9]. Technical exclusion criteria for this VA
burst study were as follows: (1) poor quality ECG-Holter recording,
(2) previous myocardial infarction (MI), and (3) poor quality CMR im-
aging. Clinical exclusion criteria for the current study were (1) absence
of successful epicardial ﬂow restoration deﬁned as TIMI ﬂow ≤ 2,(2) failure to achieve complete and stable ST recovery within 240 min
or (3) late ST re-elevation on continuous ECG-Holter. These exclusion
criteria were formed because we were interested in the additional
value of VA burst in patients with optimal epicardial reperfusion and
brisk ST-recovery. Therefore, we did not perform statistical analyses of
the groups excluded.
2.2. Angiographic TIMI ﬂow assessment
TIMI ﬂow grade assessment was performed by the angiographic
core laboratories (Academic Medical Center, Amsterdam, The
Netherlands and Maastricht University Medical Center, Maastricht,
The Netherlands) blinded to all patient and other core laboratory
data. TIMI ﬂow was graded according to the TIMI trial classiﬁcation
[14].
2.3. ECG data acquisition
Continuous, high ﬁdelity, digital, 12-lead ECG-Holter recording
(NEMON 180+, Northeast Monitoring, Maynard, MA, USA)was started
at the time of admission prior to PCI and continued for an average of
24 h. This system provided the source data for both continuous ST-
segment recovery and ventricular arrhythmia burst analysis. Quantita-
tive ST-segment recovery analysis was performed on 60 secondmedian
beat 12-lead ECGs. Quantitative ventricular arrhythmia (VA) analysis
was performed on 3-lead beat-to-beat Holter. ST and VA analyses
were performed by independent experts blinded to all other patient
and core laboratory data through the collaborative eECG core laboratory
program (Duke Clinical Research Institute/Maastricht University Medi-
cal Center eECG Core, Durham, North Carolina, USA and Maastricht,
The Netherlands), using NEMON Holter for Windows software.
2.4. Continuous ST recovery analysis
Methods and criteria for continuous 12-lead ST-segment recovery
analysis and reperfusion of the culprit lesion have been described
in detail previously [15]. In short, peak ST-segment deviation is de-
termined based on the lead with the greatest baseline deviation
taken from the most abnormal ECG recorded during monitoring. Sta-
ble and complete ST-segment recovery is deﬁned as ≥50% recovery
from previous peak ST-segment levels in the most deviated lead
within 240 min, lasting N4 h without further ST-segment evolution
(N100 μV). Late ST (re-)elevation deﬁning epicardial vessel re-
occlusion (N150 μV re-elevation in the most abnormal lead evolving
in b60 min) or microvascular insufﬁciency (N50% peak ST levels
persisting N6 h in the most abnormal lead) were used to exclude pa-
tients from the “optimal reperfusion biosignature” group included in
the current analysis.
2.5. Quantitative rhythm analysis and deﬁning VA burst
For beat-to-beat quantitative rhythm analysis on all digital 3-lead
Holter recordings, Holter 5 software (Northeast Monitoring, Maynard,
MA, USA) was used [4]. All automatically assigned waveform labels
were manually veriﬁed for each cardiac cycle from each subject to
ensure accurate VA capture according to predeﬁned criteria for ECG in-
terpretation of VAs [4,5]. To generate quantitative VA rates over a
24 hour period, total VPC counts, for which no distinction between the
types of VPCwasmade,were bundled into 5minute blocks for temporal
correlation with stable ST-segment recovery and angiographic observa-
tions (Fig. 2). Quantitative VA rates over the course of Holter recordings
were incorporated in a statistical outlier detection method to automat-
ically separate outlier events of VA rates (VA burst), if present, from
patient-speciﬁc baseline VA counts. VA bursts were deﬁned as “reperfu-
sion VA bursts” if concomitant with or subsequent to angiographic
documentation of re-established TIMI 3 ﬂow in the infarct related
Fig. 2. Example of a patientwith and a patient without VA burst. Concomitantly acquired coronary angiography assessments of pre- and post-primary percutaneous coronary intervention
TIMI ﬂow grades in two study subjects (1A and 2A) with a total occlusion in the proximal left anterior descending artery proximal (LAD); continuous digital 12-lead electrocardiography
monitoring for ST-segment recovery analysis with both subjects having ≥50% stable ST-segment recovery (1B and 2B); and complete beat-to-beat Holter monitoring for quantitative
rhythm analysis identifying (1C) or not identifying (2C) patient-speciﬁc ventricular arrhythmia ‘bursts’ by using independent statistical outlier detection methodology. Cx, circumﬂex ar-
tery; LMA, left marginal artery. Note the burst versus the background VA as depicted in 1C and 2C.
Reproduced with permission from Majidi et al. [5].
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sion VA burst’ group or the ‘no burst’ group. Statistical deﬁnition and
characterization of reperfusion VA bursts has been described in detail
by Majidi et al. [4].
2.6. CMR imaging protocol
CMR was performed 3 to 6 months after the myocardial infarction.
Images were acquired on clinical 1.5-T scanners (Philips Intera, Philips
Medical Systems, Best, The Netherlands) and Siemens Sonato/Avanto
(Siemens, Erlangen, Germany) using phased-array receiver coils ac-
cording to the routine scan protocol at each site. Localizers were ac-
quired to identify the cardiac position and the standard long- and
short-axis of the heart. Cine images were acquired in the vertical and
horizontal long axis, and multiple short-axis slices completely covering
the left ventricle, using a steady-state free-precession sequence. DE-
CMR images were obtained 10–15 min after the intravenous adminis-
tration of 0.2 mmol/kg body weight Gadolinium-based contrast agent
(Gd-DTPA, Magnevist®, Schering, Germany) in horizontal and vertical
long axis, and multiple short axis views completely covering the left
ventricle, using a segmented inversion recovery gradient-echo se-
quence (either 2D or 3D).
DE-CMR images were analyzed off-line independently by a single
experienced observer per trial, blinded to the clinical and ECG data,
using commercially available software (CAAS MRV 3.0, Pie Medical Im-
aging, Maastricht, The Netherlands for MAST study or MASS 5.1, Medis,
Leiden, The Netherlands for PREPARE trial). Both laboratories used thestandardized methods for CMR analyses which have shown to have
excellent reproducibility [16]. Statistical comparisons showed no
signiﬁcant trial difference for IS (p= 0.48) Endocardial and epicardi-
al contours were manually traced on the DE-CMR images. Final left
ventricular IS was quantiﬁed using a SI threshold of N5 SD above a re-
mote non-infarcted region and expressed as a percentage of total left
ventricular mass. Areas of microvascular obstruction (central
hypoenhancement within hyperenhanced area) were included in IS
assessment. Left ventricular end-diastolic volumes, end-systolic vol-
umes, and ejection fraction (LVEF) were determined by planimetry
of all short axis images in each patient.
2.7. Statistical analysis
Univariable comparisons for baseline characteristics and outcomes
for subjects with and without VA burst were made using the student
t-test for continuous variables that were normally distributed, the
Wilcoxon rank sum test for non-normally distributed continuous vari-
ables, and Fisher's exact test for dichotomous variables. A p-value of
b0.05 was considered statistically signiﬁcant and all tests were two-
sided. Medians are provided with their corresponding upper and
lower quartiles. Multivariable linear regression analysis was performed
to assess whether VA burst remained an independent predictor for in-
farct sizewhen corrected for baseline covariates. Covariateswere select-
ed by including known predictors for infarct size, study origin, and
treatment assignment in the multivariable model and excluding those
with p-values of b0.15. Covariates were added to a regression model
Fig. 3. Patient selection. Patient selection of combined dataset with reasons for exclusion.
TIMI = thrombolysis inmyocardial infarction, CMR= cardiac magnetic resonance, PCI =
percutaneous coronary intervention.
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software version 19 (IBM, Armonk, New York, USA).
3. Results
3.1. Patient characteristics
Of the 327 available patients that gave informed consent (n = 106
MAST and n = 221 PREPARE), 196 were included in the ﬁnal analysis
population of patients with optimal reperfusion (n = 56 MAST and
n = 140 PREPARE). Reasons for exclusions were previous MI (n =
17), presented with TIMI 3 ﬂow before PCI (n = 19), TIMI 3 ﬂow
could not be established after PCI (n = 27), no CMR was performed
(n = 26), CMR study quality was insufﬁcient to determine IS (n =
19), stable ST reperfusion was not achieved (n = 19), and occurrence
of late ST re-elevation (n = 4) (Fig. 3).
Reperfusion VA burst was observed in 154/196 (79.8%) of “optimal
reperfusion” patients. Table 1 compares the baseline characteristics be-
tween the burst and noburst groups. Other than a lower incidence of ni-
trate use before reperfusion in the VA burst group (p= 0.045), the two
groups were comparable. Reperfusion VA burst was observed in 75.5%
(111/147) of non-anterior MI patients and in 87.8% (43/49) of patients
with anterior MI location (p = 0.07). CMR was performed a median of
141 days (range of 111–317) after admission.
3.2. Burst, infarct location, ST-recovery, and ﬁnal infarct size
As shown in Fig. 4, the presence of VA burst was associated with a IS
twice as large compared to patientswithout VAburst (11.3% vs. 5.3%, re-
spectively; p = 0.001). In multivariable analyses, this correlation be-
tween VA burst and IS remained signiﬁcant (B = 3.3; p = 0.02) when
correcting for other factors related to IS, including anterior location,
age, and stroke history (Table 2). In stratiﬁed analyses based onMI loca-
tion, non-anterior IS was signiﬁcantly higher in patients with VA burst
compared to no VA burst (9.9% vs. 4.9%, respectively; p = 0.003), and
also in anterior infarct location (21.4% vs. 12.0%, respectively) although
not statistically signiﬁcant due to the small number of patients (p =
0.48). An interaction test for VA burst and anterior infarct location did
not reach statistical signiﬁcance indicating that burst did not occur
more often in the anterior population versus the non-anterior popula-
tion. IS in patients with late and/or incomplete ST-segment recovery
who were excluded from the “optimal reperfusion” cohort analyzed in
this study is shown in Fig. 5. As can be seen, IS in the absence of ST recov-
ery was signiﬁcantly higher than in patients with ST recovery (23.5%
and 19.1% vs. 5.3% and 11.3%, respectively; p = 0.002). When patients
with ST recovery were further grouped by the presence or absence of
VA burst, patients with ST recovery and VA burst had larger IS, more
comparable to the no ST recovery group. This suggests that the lack of
ST recovery leads to larger IS anyway due to the poor reperfusion qual-
ity as a result of mechanisms such as distal embolization. Furthermore,
our results show that although TIMI 3 ﬂow and ST recovery are optimal,
the occurrence of VA bursts is associated with similarly sized IS as pa-
tients without ST-recovery.
Left ventricular ejection fraction did not differ between the two
groups due to small infarct size but the enzymatic surrogate for infarct
size, CK-MB max, was signiﬁcantly higher in the population with VA
burst (210 vs 134; p = 0.001).
4. Discussion
This study provides prospective conﬁrmation in an independent pa-
tient population of the hypothesis generated byMajidi et al. [5] that the
presence of reperfusion VA burst further stratiﬁes IS in patients who
otherwise have an optimal mechanistic biosignature of brisk epicardial
TIMI ﬂow and rapid and complete ST-segment recovery. In addition to
these conﬁrmatory ﬁndings, this study is the ﬁrst to also explore VAburst in non-anterior MI cohorts, and is the ﬁrst to report serial surro-
gate mechanistic modeling of angiographic ﬂow, ST-segment recovery
and reperfusion VA burst arrhythmia using DE-CMR as a uniquely pre-
cise measure of IS.
Previousmodels of reperfusion VA burst depended on core laborato-
ry SPECT to quantify an independent IS endpoint. SPECT is well validat-
ed in larger MI, however is less reliable in smaller MI [17]. DE-CMR, on
the other hand, has superior spatial resolution and is superior in detect-
ing subendocardial infarcts and infarcts in non-anterior locationswhich
Table 1
Patient characteristics.
Burst N = 154 No burst N = 42 p
Demographics
Age (years) 58.2 ± 11.3 58.1 ± 9.3 0.94
Male 121 (78.6%) 38 (90.5%) 0.12
Comorbidities
BMI 26.9 ± 3.7 27.1 ± 3.9 0.75
Smoking current 89 (57.8%) 25 (59.5%) 0.51
Smoking previous 27 (17.5%) 10 (23.8%)
History of hypertension 36 (23.4%) 13 (31.0%) 0.32
Diabetes mellitus 10 (6.5%) 3 (7.1%) 1.00
Hypercholesteremia 30 (19.5%) 8 (19.0%) 1.00
Positive family history 62 (40.3%) 17 (40.5%) 1.00
Pre-existent AP 18 (11.7%) 9 (21.4%) 0.13
History of stroke 4 (2.6%) 2 (4.8%) 0.61
History of peripheral artery disease 5 (3.2%) 3 (7.1%) 0.37
Medication
β-Blocker 16 (10.4%) 6 (14.3%) 0.58
Acetyl salicylic acid 15 (9.7%) 7 (16.7%) 0.27
ADP-antagonist 1 (0.6%) 0 (0.0%) 1.00
Statin 20 (13.0%) 8 (19.0%) 0.33
Nitrates 0 (0.0%) 2 (4.8%) 0.045a
ACE-inhibitor 6 (3.9%) 2 (4.8%) 0.68
AT-II antagonist 9 (5.8%) 5 (11.9%) 0.18
Calcium-antagonist 8 (5.2%) 6 (14.3%) 0.08
PCI
Duration of symptoms (minutes) 186.2 ± 82.6 184.6 ± 64.8 0.91
Anterior location 43 (27.9%) 6 (14.3%) 0.07
Multiple vessel disease 51 (33.1%) 18 (42.9%) 0.28
PCI of N1 lesion 8 (5.2%) 1 (2.4%) 0.69
Side branch occlusion 2 (1.3%) 0 (0.0%) 1.00
Distal embolization 15 (9.7%) 7 (16.7%) 0.27
Presence of collaterals 8 (5.2%) 4 (9.5%) 0.29
CMR
Time to CMR 124 (100–326) 144 (113–297) 0.15
LVEF 51.1 ± 9.5 53.6 ± 9.1 0.11
Laboratory results
CK-MB max 210 (127–400) 134 (59–183) 0.001a
Results presented as mean ± standard deviation, median with quartiles (..–..), or N (%).
ACE = angiotensin converting enzyme, ADP = adenosine diphosphate, AP = angina
pectoris, AT = angiotensin, BMI = body mass index, PCI = percutaneous coronary
intervention.
a Signiﬁcant difference.
Fig. 4. Effect of VA burst on infarct size. Box plots with corresponding medians and quar-
tiles displaying the effect of VA burst for (A) infarct size for total population, (B) infarct
size* of non-anterior myocardial infarctions, and (C) infarct size of anterior myocardial in-
farctions. * signiﬁcant (p b0.05).
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aging technology is particularly important in the current study with
non-anterior STEMI. While it is noteworthy that in our data IS in anteri-
or STEMIwas not signiﬁcantly different in patients with andwithout VA
burst, we do not feel the change in imaging technology explains this dif-
ference from previous reports. IS of anterior STEMI in our data was nu-
merically double in patients with VA burst compared to those with no
burst. In our data set only 6 patients with anterior STEMI location did
not have VA burst, leaving numerical differences in IS in this subset sta-
tistically underpowered especially with the large heterogeneity in in-
farct size for anterior infarctions. The reason for this low incidence in
anterior STEMI in our population can be partly explained by the exclu-
sion of proximal LAD occlusion in the PREPARE data set secondary to
the inability to place the PROXIS device in those patients. But incidence
of anterior MI in theMAST data set was similar and no other reason ex-
cept pure coincidence could be found. Surrogate markers for infarct size
supported the ﬁndings of IS using DE-CMR. LVEF did not signiﬁcantly
differ between the two groups. Thismight be because though ISwas sig-
niﬁcantly larger in the VA burst population, they were relatively small
and therefore had minor effects on LVEF. The low incidence of anterior
infarcts might be additional factor for the preserved LVEF found. Enzy-
matic infarct size estimated using CK-MB max values did signiﬁcantly
differ as DE-CMR results showed. We acknowledge the limitations of
CK-MBmax levels for estimating infarct size and included this outcometo illustrate our ﬁndings. The population existed out of homogenous
group with brisk optimal reperfusion (TIMI 3 ﬂow) increasing the reli-
ability of CK-MB max values as an indicating marker for ﬁnal IS.
Table 2
Multivariable analysis for ﬁnal infarct size predictors.
Coefﬁcient 95% CI p-Value
Presence of VA burst 3.3 (0.5, 6.1) 0.02a
Anterior location 8.9 (6.3, 11.5) b0.001a
Age (years) 0.1 (−0.1, 0.2) 0.09
History of stroke −5.5 (−12.1, 1.1) 0.10
Constant 2.3 (0.5, 6.1) 0.02a
Constant = the constant in the regression analyses of y = ax + b, the constant being b.
a Signiﬁcant difference. R2 = 0.25.
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Even as knowledge has advanced that it is not simply the infarct ar-
tery opening but a series of key mechanistic steps that deﬁne optimal
reperfusion, each of these steps has come to provide potential therapeu-
tic targets to improve STEMI outcomes [8]. The availability of quantiﬁ-
able surrogates for each of the key mechanistic steps thus provides a
potentially important construct of a proﬁle or “biosignature” of optimal
reperfusion [19]. In the Majidi model reproduced for this analysis, brisk
angiographic TIMI ﬂow through the epicardial artery, rapid and com-
plete ST recovery reﬂecting microvascular ﬂow to the reversibly ische-
mic territory downstream, and freedom from arrhythmias reﬂecting
chemical toxicity at the cellular level constitute the extension of the op-
timal biosignature. While a number of other surrogate markers — in-
cluding serial cardiac enzyme curve areas, contrast echocardiography
and other imaging technologies—have interest in STEMI patients after
reperfusion, angiography for TIMI ﬂow and ECG-based ST-segment re-
covery and VA burst provide pragmatic advantages. First, angiography
and ECGmonitoring are fundamental for STEMI patients, and so are rou-
tinely available technologies in the clinical care setting. Secondly, TIMI
ﬂow, ST recovery and freedom from VA burst following reperfusion
are all “day zero” surrogates that can be interpreted in virtual real-
time, either for clinical or for clinical research applications.4.2. Limitations
There are several limitations to our data. First, only 50% of the pa-
tients from these combined studies had both optimal recanalizationFig. 5. Effect of stable or non-ST-recovery in combinationwith VAburst on infarct size. Box
plot with corresponding median and quartiles displaying the effect of stable ST-recovery
and the presence of VA burst for infarct size.by angiography and ST-segment recovery and all surrogates markers
analyzable for our model (Holter and DE-CMR imaging). This resulted
in a cohort too small to power subgroup observations, such as the ante-
rior MI location group. However, in this relatively small population,
with a high incidence of smaller infarct that were accurately analyzed
by DE-CMR, the results are clear and conﬁrmative for the correlation be-
tween larger IS in the event of VA burst. Furthermore this study is a
pooled cohort from two clinical trials. Combining the two trials in-
creased sample size but also has potentially confounding features. In
the multivariable model, however, study origin did not interact with
the ﬁnal IS determination. Finally, while IS has utility as an endpoint
for testing the information content of additional surrogate markers to
the biosignature of “optimal” reperfusion, clinical endpoints such as
heart failure, need for deﬁbrillators or mortality would be very mean-
ingful as further asses its clinical relevance.
5. Conclusion
Our study is unique in including both anterior and non-anterior pa-
tients for reperfusion arrhythmia analyses and correlating the ﬁndings
with infarcts size determined by DE-CMR, the current gold standard.
Our data conﬁrm the hypothesis previously suggested by Majidi et al.
[4,5,19], using the identical step-wise mechanistic “biosignature” con-
struct, that VA bursts predict larger infarct size in patients presenting
with STEMI and treated with primary PCI resulting in brisk epicardial
ﬂow restoration (TIMI 3 ﬂow) and rapid and complete ST-segment res-
olution. Future work should concentrate on analyzing the pathophysio-
logical mechanisms of VA burst with one possibility being a sign of
reperfusion injury. This would open the way to new treatment targets
such as interventional methods and drugs to prevent or treat reperfu-
sion injury.
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